A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects
- Registration Number
- NCT03914755
- Lead Sponsor
- Seagen Inc.
- Brief Summary
This study is being done to compare the pharmacokinetics (PK) and safety/tolerability of tucatinib in healthy Japanese and Caucasian participants.
Three cohorts of healthy Japanese and Caucasian men and women will be admitted to the Clinical Research Unit (CRU) and receive multiple oral doses of tucatinib over 14 days with and without food.
Subjects will be in the study for up to 45 days, including the screening period.
Due to practical considerations, each cohort will be dosed sequentially (this is not a dose escalation study).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
-
Body mass index between 18 and 32 kg/m^2 and a total body weight between 50 and 100 kg
-
In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiograms, vital signs measurements, or clinical laboratory evaluations
-
Female subjects participating in the study will be of non-childbearing potential. Male subjects will be surgically sterile for at least 90 days or will agree to use contraception during the study and for 90 days after last dose of study drug.
-
Japanese subjects:
- Must have been born in Japan
- Must have 2 biological Japanese parents and 4 biological Japanese grandparents as confirmed by interview
- Must have spent less than 10 years outside of Japan, and has no significant changes in lifestyle, including diet, since leaving Japan
- Significant history of metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
- Current condition possibly affecting drug absorption
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
- History of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs
- History of alcoholism or drug/chemical abuse within 2 years of check-in
- History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects
- Positive hepatitis panel and/or positive human immunodeficiency (HIV) test
- Liver function tests, serum creatinine, hemoglobin, or hematocrit values outside of the normal reference range
- Single 12-lead ECG demonstrating QTcF>450 msec for males or >470 msec for females
- Participation in a clinical study involving administration of an investigational drug in the past 30 days from last dose or 5 half-lives (whichever is longer)
- Use of any products known to alter drug absorption, metabolism or elimination processes, including St. John's wort and known strong inhibitors or inducers of CYP3A4 or CYP2C8, within 30 days
- Use of or intention to use any prescription or nonprescription products, including vitamins, minerals and herbal preparations within 14 days
- Use of tobacco- or nicotine-containing products within 3 months
- Receipt of blood products within 2 months
- Donation of blood from 56 days before the Screening Visit, plasma from 2 weeks before the Screening Visit or platelets from 6 weeks before the Screening Visit
- Poor peripheral venous access
- Have previously completed or withdrawn from this study or any other study investigating tucatinib and have previously received the study drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohort 2 Tucatinib 150 mg twice daily on Days 1-13 and once daily on Day 14 Cohort 1 Tucatinib 50 mg twice daily on Days 1-13 and once daily on Day 14 Cohort 3 Tucatinib 300 mg twice daily on Days 1-13 and once daily on Day 14
- Primary Outcome Measures
Name Time Method Cmax of ONT-993 14 days Time of the maximum observed concentration (tmax) of tucatinib 14 days AUC from time 0 to the time of last quantifiable concentration (AUClast) of tucatinib 14 days Metabolite-to-parent molar ratio based on AUC (MRAUC) of ONT-993 14 days Maximum observed concentration (Cmax) of tucatinib 14 days Tmax of ONT-993 14 days AUC from time 0 to 12 hours postdose (AUC0-12hr) of tucatinib 14 days AUC from time 0 extrapolated to infinity (AUC0-inf) of tucatinib 1 day AUC from time 0 extrapolated to infinity (AUC0-inf) of ONT-993 1 day Percentage of AUC0-inf due to extrapolation (%AUCextrap) of tucatinib 1 day %AUCextrap of ONT-993 1 day Apparent volume of distribution during the terminal phase (Vz/F) of tucatinib 14 days AUC0-12hr of ONT-993 14 days Apparent total clearance (CL/F) of tucatinib 14 days AUClast of ONT-993 14 days
- Secondary Outcome Measures
Name Time Method Incidence of adverse events (AEs) 17 days
Trial Locations
- Locations (1)
PAREXEL International, Early Phase Clinical Unit - Los Angeles
🇺🇸Glendale, California, United States